Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.
Inclusion Criteria:
Exclusion Criteria: